• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SNDL Reports Full Year and Fourth Quarter 2023 Financial and Operational Results

    3/21/24 5:58:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    The Company reports record net revenue and gross profit in 2023 and achieves positive cash flow in the second half of 2023

    CALGARY, AB, March 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2023. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

    SNDL Inc. logo (CNW Group/SNDL Inc.)

    SNDL has also posted a supplemental investor presentation and shareholder letter on its website, found at https://sndl.com.

    The Company will hold a conference call and webcast at 10 a.m. EDT (8 a.m. MDT) on Thursday, March 21, 2024. The conference call details can be found below.

    FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL AND OPERATIONAL HIGHLIGHTS

    • Record net revenue for 2023 of $909.0 million compared to $712.2 million in 2022, an increase of 28%. Net revenue for the fourth quarter of 2023 was $248.5 million, compared to $240.4 million in the fourth quarter of 2022, an increase of 3%, with sequential growth in the Cannabis Retail and Cannabis Operations segments.



    • Gross profit grew to a record $190.4 million, or 21% of sales, for 2023, compared to $140.4 million, or 20% of sales, in the previous year, representing an increase of 36%. Record gross profit of $57.3 million, or 23% of sales, for the fourth quarter of 2023, compared to $43.6 million, or 18% of sales, in the fourth quarter of 2022. This improvement underscores the benefit of our supply chain optimization strategy, including the closure of the Olds, Alberta cultivation facility in October 2023.



    • Cash flow was negative $84.5 million in 2023, compared to negative $278.7 million, a 70% year-over-year improvement. In the fourth quarter of 2023, cash flow was negative $6.9 million, compared to negative $11.8 million in the fourth quarter of 2022, a 42% improvement. SNDL achieved positive cash flow in the second half of 2023, totaling $9.6 million.



    • Positive free cash flow1 achieved in the second half of 2023, totaling $17.7 million. This achievement was marked by positive free cash flow of $16.3 million in the third quarter of 2023 and $1.4 million in the fourth quarter of 2023, despite the working capital build up in anticipation of the holiday season in the latter quarter.



    • Operating income loss of $162.8 million for 2023, partly attributable to restructuring charges of $19.6 million and goodwill impairment of $29.0 million. This compares to a loss of $347.8 million in the previous year, marking a 53% improvement driven by revenue and margin expansion. Operating income loss of $84.9 million for the fourth quarter of 2023, including $13.3 million of restructuring cost and $29.0 million of goodwill impairment, compared to a loss of $154.6 million in the fourth quarter of 2022, a 45% improvement.



    • Adjusted EBITDA from continuing operations2 was $29.2 million in 2023, compared to an Adjusted EBITDA from continuing operations loss of $15.8 million in the previous year. Adjusted EBITDA from continuing operations was $3.5 million for the fourth quarter of 2023, compared to an Adjusted EBITDA from continuing operations loss of $7.5 million in the fourth quarter of 2022, a 147% improvement.



    • 2023 was a transformational year for SNDL, laying the groundwork for enhanced financial and operational performance in 2024 and beyond.
      • Acquired The Valens Company Inc. ("Valens"), creating a low-cost vertically integrated Canadian cannabis company.
      • Optimized the Cannabis Operations footprint by closing the Olds, Alberta facility and transitioning remaining cultivation activities to Atholville, New Brunswick, while consolidating manufacturing and processing activities in Kelowna, British Columbia.
      • Optimized and rationalized the Company's cannabis brand and SKU portfolio.
      • Enhanced the proprietary data program in the Cannabis Retail segment, significantly boosting margin profits.
      • Enhanced the leadership team by appointing a new Chief Financial Officer and President of Cannabis, among other key senior roles.



    • $766.7 million of unrestricted cash, marketable securities and investments and no outstanding debt, with $195 million of unrestricted cash at December 31, 2023. SNDL has not raised cash through share offerings since June 2021.

    "2023 was a year of significant financial success for SNDL, including record-breaking revenue and gross profit, and the achievement of free cash flow in the second half of the year," said Zach George, Chief Executive Officer of SNDL. "The generation of stabilized free cash flow continues to be a top priority for our team, and I am proud that we delivered on this stated objective during the last two quarters. This period was foundational as we acquired Valens, welcomed top-tier leaders and streamlined our balance sheet, positioning SNDL for improved performance in 2024 and beyond. In our Cannabis Operations, we undertook a comprehensive overhaul, establishing a solid foundation for future success. We refined our brand portfolio, optimized our operational footprint, and enhanced our procurement strategies, with early signs of a positive impact in 2024. We continued to build on the Liquor Retail segment's stable base, focusing on strategies that enhance margins through our data program, improved inventory management, and emerging e-commerce program. We delivered record results in revenue, gross profit, and cash flow within our Cannabis Retail segment, driven by the expansion of both our owned portfolio and network data programs. We also announced the launch of SunStream USA Group through our joint venture partner, SunStream Bancorp Inc., highlighting our commitment to the U.S. market as a key catalyst for growth. Our consumer-centric approach and relentless focus on quality is the cornerstone of our strategy, supported by a strong balance sheet and improving operations. This approach lays the groundwork for a business positioned to create value for shareholders through high-quality unadjusted earnings and robust free cash flow."

    ____________________________________

    1 Free cash flow is a non-IFRS financial measure that is not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. See "Specified Financial Measures – Free Cash Flow" below.  

    2 Adjusted EBITDA from continuing operations is a non-IFRS financial measure that is not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. See "Specified Financial Measures – Adjusted EBITDA from continuing operations" below. 



    FULL YEAR AND FOURTH QUARTER 2023 KEY FINANCIAL METRICS

    OPERATING SEGMENTS





































    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Year ended December 31, 2023





































    Net revenue



    578,895





    289,980





    87,071





    —





    (46,940)





    909,006



    Gross profit



    137,286





    73,690





    (20,561)





    —





    —





    190,415



    Operating income (loss)



    24,630





    4,919





    (112,445)





    11,746





    (91,668)





    (162,818)



    Adjusted operating income (loss) (1)



    24,630





    4,919





    (52,429)





    11,746





    (86,541)





    (97,675)



    Three months ended December 31, 2023





































    Net revenue



    159,493





    75,152





    26,044





    —





    (12,239)





    248,450



    Gross profit



    38,396





    20,045





    (1,105)





    —





    —





    57,336



    Operating income (loss)



    10,102





    (849)





    (65,653)





    (5,217)





    (23,322)





    (84,939)



    Adjusted operating income (loss) (1)



    10,102





    (849)





    (7,619)





    (5,217)





    (23,433)





    (27,016)



    Year ended December 31, 2022





































    Net revenue



    462,180





    205,610





    44,407





    —





    —





    712,197



    Gross profit



    106,307





    47,334





    (13,266)





    —





    —





    140,375



    Operating income (loss)



    20,619





    (180,956)





    (29,372)





    (91,275)





    (66,790)





    (347,774)



    Adjusted operating income (loss) (1)



    20,619





    (8,347)





    (27,522)





    (91,945)





    (66,790)





    (173,985)



    Three months ended December 31, 2022





































    Net revenue



    159,745





    68,402





    12,258





    —





    —





    240,405



    Gross profit



    36,927





    15,650





    (9,009)





    —





    —





    43,568



    Operating income (loss)



    (3,898)





    (98,444)





    (12,442)





    (19,543)





    (20,319)





    (154,646)



    Adjusted operating income (loss) (1)



    (3,898)





    (10,201)





    (12,442)





    (19,331)





    (20,319)





    (66,191)



    (1)    Adjusted operating income (loss) is a non-IFRS financial measure that is not defined by IFRS and, therefore may not be comparable to similar measures reported by other companies. See "Specified Financial Measures – Adjusted operating income (loss)" below.



    FULL YEAR AND FOURTH QUARTER 2023 RESULTS

    SNDL's business is operated and reported in four segments: Liquor Retail, Cannabis Retail, Cannabis Operations and Investments. 

    Liquor Retail

    SNDL is Canada's largest private sector liquor retailer, operating 170 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond", "Liquor Depot" and "Ace Liquor". Revenue comparisons for 2022 include operations from March 31 to December 31, 2022, following the acquisition of Alcanna Inc.

    • Net revenue for Liquor Retail sales for the three banners combined was $578.9 million in 2023, compared to $462.2 million in 2022, a 25% increase year-over-year. Net revenue was $159.5 million in the fourth quarter of 2023, showcasing consistent revenue compared to $159.7 million in the same quarter in the prior year, driven by stable same-store sales.
    • Gross profit in 2023 was $137.3 million, or 24% of sales, compared to $106.3 million, or 23% of sales, in 2022, a 29% increase year-over-year. Gross profit was $38.4 million, or 24% of sales, in the fourth quarter of 2023, compared to $36.9 million, or 23% of sales, in the fourth quarter of 2022. This improvement was mainly driven by procurement productivity and product mix management initiatives.
    • SNDL launched its proprietary data licensing program for Liquor Retail in the fourth quarter of 2023 and anticipates revenue generation starting in the first quarter of 2024, helping to further enhance the segment's profit margins.
    • Private label sales, a substantial driver of profitable growth, increased by 28% compared to the full year of 2022 and 28% compared to the fourth quarter of 2022. This increase is driven by further additions to the private label offerings, particularly within the value segment. The Company plans to extend its private label line-up with wine varietals sourced from distinguished regions and notable winemakers, all priced attractively, which is expected to contribute to SNDL's margin growth while further distinguishing its liquor retail banners.
    • The Company plans to open a Wine and Beyond location in Airdrie, Alberta, in the second quarter of 2024 to further build on the success of the experiential, destination approach of the banner.
    • As of March 21, 2024, the Ace Liquor store count is 138, the Liquor Depot store count is 20, and the Wine and Beyond store count is 12.

    Cannabis Retail

    With its 63% ownership interest in Nova Cannabis Inc. ("Nova"), SNDL is Canada's largest private-sector cannabis retailer, operating 187 locations under its four retail banners: "Value Buds", "Spiritleaf", "Superette", and "Firesale Cannabis". SNDL's Cannabis Retail strategy is based on several pillars, including the quality of its store locations, its range of products, and the unique experiences it provides customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy. Revenue comparisons for 2022 include operations of Nova retail stores for the period of March 31, 2022, to December 31, 2022.

    • Net revenue from the Cannabis Retail segment was a record $290.0 million in 2023, compared to $205.6 million in 2022, an increase of 41% year-over-year. Net revenue in the fourth quarter of 2023 was $75.2 million, compared to $68.4 million in the fourth quarter of 2022, a 10% increase year-over-year in reported sales.
    • For stores open in the fourth quarter of 2022 and 2023, same-store sales increased 1.9%.
    • Record gross profit from the Cannabis Retail segment, with $73.7 million in 2023, or 25% of sales, compared to $47.3 million in 2022, or 23% of sales, a 56% increase year-over-year. Gross profit for the Cannabis Retail segment was $20.0 million, or 27% of sales, in the fourth quarter of 2023, compared to $15.7 million, or 23% of sales, in the fourth quarter of 2022, a 27% increase year-over-year. The increase showcases the Company's efforts in continued margin expansion initiatives.
    • Nova's proprietary data licensing program generated revenue of $12.3 million in 2023, compared to $4.2 million in 2022, a 193% increase year-over-year. Proprietary licensing revenues for the fourth quarter of 2023 increased to $4.2 million.
    • In February 2023, SNDL announced the acquisition of five Superette stores in Ontario.
    • As of March 21, 2024, the Spiritleaf store count is 85 (21 corporate stores and 64 franchise stores), the Superette store count is four corporate stores, the Firesale Cannabis store count is two corporate stores and the Value Buds store count is 96 corporate stores.

    Cannabis Operations

    SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy. Cannabis Operations include the operations of Valens for the period of January 18, 2023, to December 31, 2023.

    • The Cannabis Operations segment achieved a record net revenue of $87.1 million in 2023, reflecting a substantial 96% increase from $44.4 million in 2022. Net revenue for the fourth quarter of 2023 was $26.0 million, up 111% from $12.3 million in the same quarter of the previous year. The net revenue in the fourth quarter of 2023 represents the highest revenue achieved since Q3 2019, which was $28.0 million, before market saturation and price challenges.
    • Gross margin was negative $20.6 million in 2023, compared to negative $13.3 million in 2022. Gross profit for the fourth quarter of 2023 was negative $1.1 million, compared to negative $9.0 million in the fourth quarter of 2022. This 88% improvement in gross profit during the fourth quarter is largely attributable to the strategic decision to close the Olds, Alberta facility.
    • During 2023, SNDL optimized its facility footprint to bolster competitiveness and profitability. The Company is leveraging an enhanced procurement strategy, while consolidating the remaining cultivation activities at its Atholville, New Brunswick facility, and centralizing manufacturing, processing, and production operations in Kelowna, British Columbia.
    • The Company undertook an intensive rationalization and revitalization of its cannabis portfolio, reducing the SKU count from 327 at the beginning of 2023 to 125 at the end of 2023 to better focus on key consumer categories in vape, flower and pre-rolls.
    • SNDL monetized nearly 35 million grams of excess biomass, strategically optimizing days-on-hand inventory.
    • The Company has implemented innovative strategies in its Atholville facility to improve cultivation, resulting in an average annual yield of 104 grams per square foot and an average THC potency result of 25%.

    Investments

    • For the year ended December 31, 2023, the Company had deployed capital to a portfolio of cannabis-related investments with a carrying value of $571.6 million, including $538.3 million to SunStream.
    • In 2023, the investment portfolio generated positive operating income of $12.2 million compared to a loss of $91.4 million for the previous year. The interest and fee revenue for 2023 was $14.0 million compared to $16.7 million for the previous year. Share of profit of equity-accounted investees for the year ended December 31, 2023, was $6.8 million compared to a loss of $43.0 million for the year ended December 31, 2022.
    • SunStream is a joint venture sponsored by SNDL. During 2023, SunStream directed the formation of the SunStream USA group of companies ("SunStream USA Group") in connection with the restructuring of certain loans provided by SunStream. SunStream USA Group is anticipated to be a U.S. platform with one or more independent third-party investors, which will be independently managed and governed. The SunStream USA Group structure is anticipated to be reviewed by the Nasdaq, as the relevant listing authority for SNDL.
    • At the end of the fourth quarter of 2023, the credit portfolio controlled by SunStream comprised five investments: Jushi Holdings Inc., SKYMINT Brands ("Skymint"), Ascend Wellness Holdings, Surterra Holdings, Inc. d/b/a Parallel ("Parallel"), and Columbia Care Inc.
    • On September 22, 2023, an affiliate of SunStream entered into restructuring arrangements relating to investments in Parallel, which contemplate the foreclosure, to a SunStream USA entity, of certain Parallel cannabis operations in Florida, Massachusetts, Texas, and Nevada (the "Parallel Transaction").
    • On October 23, 2023, an affiliate of SunStream announced a receivership court order granting the sale of certain assets of Skymint to a SunStream USA Group entity (the "Skymint Transaction").
    • The Parallel Transaction and Skymint Transaction are anticipated to close in 2024 and are subject to certain conditions and regulatory approvals.

    Equity Position

    • $766.7 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at December 31, 2023, resulting in a net book value of $1.2 billion.
    • On November 13, 2023, the Company announced that its board of directors had approved a renewal of the share repurchase program upon its expiry on November 20, 2023. The Company's share repurchase program continues to be available to lower the outstanding share float. SNDL will continue to assess opportunities to utilize the program to the extent that management believes it is in the best interest of SNDL's shareholders. For the three months ended December 31, 2023, the Company did not purchase common shares for cancellation.

    This press release is intended to be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the years ended December 31, 2023 and December 31, 2022, and the accompanying Management's Discussion and Analysis ("MD&A"). These documents are available under the Company's profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.  

    CONFERENCE CALL  

    The Company will hold a conference call and webcast at 10 a.m. EDT (8 a.m. MDT) on Thursday, March 21, 2024.

    WEBCAST ACCESS

    To access the live webcast of the call, please visit the following link:

    https://services.choruscall.ca/links/sndl2023q4.html

    REPLAY

    A telephone replay will be available for one month. To access the replay, dial:

    Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010

    When prompted, enter Replay Access Code: 0739 #

    The webcast archive will be available for three months via the link provided above.

    ABOUT SNDL INC. 

    SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL." SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. SNDL is a licensed cannabis producer and one of the largest vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Palmetto, Bon Jak, Versus, Value Buds, and Vacay. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information on SNDL, please go to https://sndl.com/.

    Forward-Looking Information Cautionary Statement

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, the Company's ability to achieve improved profitability, growth and efficiencies across all segments, or its goal of sustainable, positive gross margin and positive free cash flow, revenue generation from the Liquor Retail proprietary data licensing program, expansion of product offerings (including the expected expansion of the Company's wine private label), the impact of rationalization initiatives on revenue and margins within the Cannabis Operations segment and owned retail locations, the expansion and additional cost savings at the Atholville facility, performance of the Company's investments, including through the SunStream joint venture and SunStream USA Group, the receipt of regulatory and listing authority approvals necessary to implement the proposed SunStream USA Group investment structure, the ability to realize expected cost savings in relation to the Valens Acquisition, expected run-rate synergies and expected proceeds from future asset sales, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as "aim", "anticipate", "assume", "believe", "contemplate", "continue", "could", "due", "estimate", "expect", "goal", "intend", "may", "objective", "plan", "predict", "potential", "positioned", "pioneer", "seek", "should", "target", "will", "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which it operates and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Risk Factors" in the Company's Annual Information Form dated March 20, 2024, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. 

    Consolidated Statement of Loss and Comprehensive Loss

    (Expressed in thousands of Canadian dollars, except per share amounts)





    Year ended

    December 31







    2023





    2022



    Gross revenue





    957,725







    729,694



    Excise taxes





    48,719







    17,497



    Net revenue





    909,006







    712,197



    Cost of sales





    689,338







    558,089



    Inventory impairment and obsolescence





    30,644







    7,012



    Gross profit before fair value adjustments





    189,024







    147,096



    Change in fair value of biological assets





    (7,936)







    (1,309)



    Change in fair value realized through inventory





    9,327







    (5,412)



    Gross profit





    190,415







    140,375





















    Interest and fee revenue





    14,517







    16,739



    Investment loss





    (9,258)







    (65,164)



    Share of profit (loss) of equity-accounted investees





    6,758







    (43,002)





















    General and administrative





    199,725







    140,168



    Sales and marketing





    15,045







    8,417



    Research and development





    324







    2,448



    Depreciation and amortization





    60,216







    40,945



    Share-based compensation





    15,400







    9,671



    Restructuring costs (recovery)





    19,573







    (670)



    Asset impairment





    54,967







    196,033



    Gain on cancellation of contracts





    —







    (290)



    Operating income (loss)





    (162,818)







    (347,774)





















    Transaction costs





    (3,718)







    (1,352)



    Finance costs, net





    (11,362)







    (41,314)



    Change in estimate of fair value of derivative warrants





    6,602







    10,783



    Foreign exchange loss





    (367)







    (19)



    Loss on disposition of assets





    (353)







    (94)



    Loss before income tax





    (172,016)







    (379,770)



    Income tax recovery





    —







    7,342



    Net loss from continuing operations





    (172,016)







    (372,428)



    Net loss from discontinued operations





    (4,535)







    —



    Net loss





    (176,551)







    (372,428)





















    Equity-accounted investees - share of other comprehensive income (loss)





    (12,771)







    24,581



    Comprehensive loss





    (189,322)







    (347,847)





















    Net loss from continuing operations attributable to:

















    Owners of the Company





    (168,125)







    (335,114)



    Non-controlling interest





    (3,891)







    (37,314)









    (172,016)







    (372,428)



    Net loss attributable to:

















    Owners of the Company





    (172,660)







    (335,114)



    Non-controlling interest





    (3,891)







    (37,314)









    (176,551)







    (372,428)



    Comprehensive loss attributable to:

















    Owners of the Company





    (185,431)







    (310,533)



    Non-controlling interest





    (3,891)







    (37,314)



     

    Consolidated Statement of Financial Position

    (Expressed in thousands of Canadian dollars)

    As at

    December 31, 2023



    December 31, 2022

















    Assets













    Current assets













    Cash and cash equivalents



    195,041





    279,586



    Restricted cash



    19,891





    19,338



    Marketable securities



    225





    21,926



    Accounts receivable



    27,059





    22,636



    Biological assets



    429





    3,477



    Inventory



    129,060





    127,782



    Prepaid expenses and deposits



    22,464





    10,110



    Investments



    3,400





    6,552



    Assets held for sale



    6,375





    6,375



    Net investment in subleases



    2,970





    3,701







    406,914





    501,483



    Non-current assets













    Long-term deposits and receivables



    4,837





    8,584



    Right of use assets



    129,679





    134,154



    Property, plant and equipment



    152,916





    143,409



    Net investment in subleases



    18,396





    19,618



    Intangible assets



    73,149





    74,885



    Investments



    29,660





    90,702



    Equity-accounted investees



    538,331





    519,255



    Goodwill



    119,282





    67,260



    Total assets



    1,473,164





    1,559,350

















    Liabilities













    Current liabilities













    Accounts payable and accrued liabilities



    68,210





    48,153



    Lease liabilities



    30,537





    30,206



    Derivative warrants



    4,400





    11,002







    103,147





    89,361



    Non-current liabilities













    Lease liabilities



    136,492





    139,625



    Other liabilities



    4,185





    2,709



    Total liabilities



    243,824





    231,695

















    Shareholders' equity













    Share capital



    2,375,950





    2,292,810



    Warrants



    2,260





    2,260



    Contributed surplus



    73,014





    68,961



    Contingent consideration



    2,279





    2,279



    Accumulated deficit



    (1,260,851)





    (1,091,999)



    Accumulated other comprehensive income



    19,417





    32,188



    Total shareholders' equity



    1,212,069





    1,306,499



    Non-controlling interest



    17,271





    21,156



    Total liabilities and shareholders' equity



    1,473,164





    1,559,350



     

    Consolidated Statement of Cash Flows

    (Expressed in thousands of Canadian dollars)





    Year ended

    December 31







    2023





    2022



    Cash provided by (used in):

















    Operating activities

















    Net loss for the period





    (176,551)







    (372,428)



    Adjustments for:

















    Income tax recovery





    —







    (7,342)



    Interest and fee revenue





    (14,517)







    (16,739)



    Change in fair value of biological assets





    7,936







    1,309



    Share-based compensation





    15,400







    9,671



    Depreciation and amortization





    64,946







    47,322



    Loss on disposition of assets





    353







    94



    Inventory impairment and obsolescence





    30,644







    7,012



    Finance costs, net





    11,362







    41,314



    Change in estimate of fair value of derivative warrants





    (6,602)







    (10,783)



    Unrealized foreign exchange gain





    (13)







    (16)



    Transaction costs





    1,221







    —



    Asset impairment





    54,967







    196,033



    Share of (profit) loss of equity-accounted investees





    (6,758)







    43,002



    Realized loss on settlement of marketable securities





    138,874







    —



    Unrealized (gain) loss on marketable securities





    (129,616)







    65,553



    Additions to marketable securities





    —







    (3,500)



    Proceeds from settlement of marketable securities





    6,704







    —



    Income distributions from equity-accounted investees





    —







    1,661



    Interest received





    13,563







    13,403



    Exercise of cash-settled deferred share units





    —







    (204)



    Change in non-cash working capital





    (32,875)







    (22,073)



    Net cash used in operating activities from continuing operations





    (20,962)







    (6,711)



    Net cash provided by operating activities from discontinued operations





    4,314







    —



    Net cash used in operating activities





    (16,648)







    (6,711)



    Investing activities

















    Additions to property, plant and equipment





    (7,845)







    (10,666)



    Additions to intangible assets





    (87)







    (197)



    Additions to investments





    (732)







    (75,598)



    Additions to equity-accounted investees





    (25,089)







    (119,137)



    Proceeds from disposal of property, plant and equipment





    1,213







    4,000



    Acquisitions, net of cash acquired





    3,695







    (28,640)



    Change in non-cash working capital





    4,028







    74



    Net cash used in investing activities from continuing operations





    (24,817)







    (230,164)



    Net cash used in investing activities from discontinued operations





    —







    —



    Net cash used in investing activities





    (24,817)







    (230,164)



    Financing activities

















    Change in restricted cash





    (553)







    7,675



    Payments on lease liabilities, net





    (41,013)







    (27,693)



    Repurchase of common shares, net of costs





    (1,536)







    (13,390)



    Proceeds from issuance of shares, net of costs





    —







    22



    Distributions declared by subsidiaries





    (20)







    (24)



    Repayment of long-term debt





    —







    (10,000)



    Change in non-cash working capital





    42







    1,620



    Net cash used in financing activities from continuing operations





    (43,080)







    (41,790)



    Net cash used in financing activities from discontinued operations





    —







    —



    Net cash used in financing activities





    (43,080)







    (41,790)



    Change in cash and cash equivalents





    (84,545)







    (278,665)



    Cash and cash equivalents, beginning of period





    279,586







    558,251



    Cash and cash equivalents, end of period





    195,041







    279,586



     

    SPECIFIED FINANCIAL MEASURES 

    Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team.

    ADJUSTED EBITDA FROM CONTINUING OPERATIONS

    Adjusted EBITDA from continuing operations is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA from continuing operations provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results in a similar manner to its management team. The Company defines adjusted EBITDA from continuing operations as net earnings (loss) from continuing operations before finance costs, change in estimate of fair value of derivative warrants, depreciation and amortization, loss (gain) on cancellation of contracts, income tax expense (recovery) and excluding change in fair value of biological assets, change in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, realized gains or losses on marketable securities, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, inventory impairment (recovery) and obsolescence, restructuring costs (recovery) and transaction costs. The Company presents both consolidated or total adjusted EBITDA from continuing operations and adjusted EBITDA from continuing operations by operating segment. 

    OPERATING SEGMENTS





























    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Year ended December 31, 2023





































    Net earnings (loss) from continuing operations



    19,190





    1,310





    (112,159)





    8,429





    (88,786)





    (172,016)



    Adjustments:





































    Finance costs



    5,274





    3,526





    (755)





    3,317





    —





    11,362



    Change in estimate of fair value of derivative

    warrants



    —





    (2)





    —





    —





    (6,600)





    (6,602)



    Depreciation and amortization



    35,662





    15,820





    3,835





    —





    4,899





    60,216



    Change in fair value of biological assets



    —





    —





    7,936





    —





    —





    7,936



    Change in fair value realized through

    inventory



    —





    —





    (9,327)





    —





    —





    (9,327)



    Unrealized foreign exchange (gain) loss



    (2)





    —





    (11)





    —





    —





    (13)



    Unrealized (gain) loss on marketable

    securities



    —





    —





    651





    (130,267)





    —





    (129,616)



    Realized loss on marketable securities



    —





    —





    —





    138,874





    —





    138,874



    Share-based compensation



    —





    6





    —





    —





    15,394





    15,400



    Asset impairment



    1,640





    5,047





    48,280





    —





    —





    54,967



    Loss (gain) on disposition of PP&E



    (25)





    79





    299





    —





    —





    353



    Cost of sales non-cash component (1)



    —





    —





    3,736





    —





    —





    3,736



    Inventory impairment (recovery) and

    obsolescence



    —





    —





    30,644





    —





    —





    30,644



    Restructuring costs (recovery)



    —





    —





    14,446





    —





    5,127





    19,573



    Transaction costs



    —





    —





    —





    —





    3,718





    3,718



    Adjusted EBITDA from continuing operations



    61,739





    25,786





    (12,425)





    20,353





    (66,248)





    29,205



    (1) Cost of sales non-cash component is comprised of depreciation expense



     

    OPERATING SEGMENTS





























    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended December 31, 2023





































    Net earnings (loss) from continuing operations



    8,990





    (1,920)





    (65,434)





    (4,858)





    (22,201)





    (85,423)



    Adjustments:





































    Finance costs



    1,121





    1,070





    (243)





    (359)





    —





    1,589



    Change in estimate of fair value of derivative

    warrants



    —





    —





    —





    —





    (2,400)





    (2,400)



    Depreciation and amortization



    7,719





    4,429





    1,085





    —





    1,527





    14,760



    Change in fair value of biological assets



    —





    —





    1,169





    —





    —





    1,169



    Change in fair value realized through

    inventory



    —





    —





    (3,999)





    —





    —





    (3,999)



    Unrealized foreign exchange (gain) loss



    —





    —





    (57)





    —





    —





    (57)



    Unrealized (gain) loss on marketable

    securities



    —





    —





    40





    —





    —





    40



    Realized loss on marketable securities



    —





    —





    —





    —





    —





    —



    Share-based compensation



    —





    —





    —





    —





    3,925





    3,925



    Asset impairment



    —





    4,481





    46,238





    —





    —





    50,719



    Loss (gain) on disposition of PP&E



    (18)





    —





    96





    —





    —





    78



    Cost of sales non-cash component (1)



    —





    —





    462





    —





    —





    462



    Inventory impairment (recovery) and

    obsolescence



    —





    —





    8,050





    —





    —





    8,050



    Restructuring costs (recovery)



    —





    —





    13,398





    —





    (111)





    13,287



    Transaction costs



    —





    —





    —





    —





    1,279





    1,279



    Adjusted EBITDA from continuing operations



    17,812





    8,060





    805





    (5,217)





    (17,981)





    3,479



    (1) Cost of sales non-cash component is comprised of depreciation expense



     

    OPERATING SEGMENTS





























    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Year ended December 31, 2022





































    Net earnings (loss) from continuing operations



    17,726





    (183,055)





    (29,618)





    (120,020)





    (57,461)





    (372,428)



    Adjustments:





































    Finance costs



    2,845





    2,155





    227





    36,087





    —





    41,314



    Change in estimate of fair value of derivative

    warrants



    —





    (83)





    —





    —





    (10,700)





    (10,783)



    Loss (gain) on cancellation of contracts



    —





    —





    (290)





    —





    —





    (290)



    Depreciation and amortization



    17,025





    9,920





    199





    —





    13,801





    40,945



    Income tax recovery



    —





    —





    —





    (7,342)





    —





    (7,342)



    Change in fair value of biological assets



    —





    —





    1,309





    —





    —





    1,309



    Change in fair value realized through

    inventory



    —





    —





    5,412





    —





    —





    5,412



    Unrealized foreign exchange (gain) loss



    10





    (4)





    (22)





    —





    —





    (16)



    Unrealized (gain) loss on marketable

    securities



    —





    —





    —





    65,553





    —





    65,553



    Share-based compensation



    —





    297





    —





    —





    9,374





    9,671



    Asset impairment



    10,079





    181,665





    4,289





    —





    —





    196,033



    Loss (gain) on disposition of PP&E



    48





    27





    19





    —





    —





    94



    Cost of sales non-cash component (1)



    —





    —





    7,003





    —





    —





    7,003



    Inventory impairment (recovery) and

    obsolescence



    —





    —





    7,012





    —





    —





    7,012



    Restructuring costs (recovery)



    —





    —





    —





    (670)





    —





    (670)



    Transaction costs



    —





    —





    —





    —





    1,352





    1,352



    Adjusted EBITDA from continuing operations



    47,733





    10,922





    (4,460)





    (26,392)





    (43,634)





    (15,831)



    (1) Cost of sales non-cash component is comprised of depreciation expense



     

    OPERATING SEGMENTS





























    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended December 31, 2022





































    Net earnings (loss) from continuing operations



    (1,316)





    (98,374)





    (12,932)





    (30,017)





    (18,932)





    (161,571)



    Adjustments:





































    Finance costs



    (2,599)





    (57)





    19





    9,098





    —





    6,461



    Change in estimate of fair value of derivative

    warrants



    —





    (27)





    —





    —





    (3,900)





    (3,927)



    Loss (gain) on cancellation of contracts



    —





    —





    (290)





    —





    —





    (290)



    Depreciation and amortization



    11,303





    3,879





    190





    —





    6,251





    21,623



    Income tax recovery



    —





    —





    —





    1,376





    —





    1,376



    Change in fair value of biological assets



    —





    —





    2,712





    —





    —





    2,712



    Change in fair value realized through

    inventory



    —





    —





    279





    —





    —





    279



    Unrealized foreign exchange (gain) loss



    3





    (4)





    25





    —





    —





    24



    Unrealized (gain) loss on marketable

    securities



    —





    —





    —





    6,868





    —





    6,868



    Share-based compensation



    —





    372





    —





    —





    2,588





    2,960



    Asset impairment



    10,079





    97,299





    283





    —





    —





    107,661



    Loss (gain) on disposition of PP&E



    17





    14





    471





    —





    —





    502



    Cost of sales non-cash component (1)



    —





    —





    1,702





    —





    —





    1,702



    Inventory impairment (recovery) and

    obsolescence



    —





    —





    3,467





    —





    —





    3,467



    Restructuring costs (recovery)



    —





    —





    —





    212





    —





    212



    Transaction costs



    —





    —





    —





    —





    2,392





    2,392



    Adjusted EBITDA from continuing operations



    17,487





    3,102





    (4,074)





    (12,463)





    (11,601)





    (7,549)



    (1) Cost of sales non-cash component is comprised of depreciation expense



     

    ADJUSTED OPERATING INCOME (LOSS)

    Adjusted operating income (loss) a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted operating income (loss) provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery) goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended December 31, 2023



    Operating income (loss)



    10,102





    (849)





    (65,653)





    (5,217)





    (23,322)





    (84,939)



    Adjustments:





































    Restructuring costs (recovery)



    —





    —





    13,398





    —





    (111)





    13,287



    Intangible asset impairments



    —





    —





    29,000





    —





    —





    29,000



    Impairments triggered by restructuring



    —





    —





    15,636





    —





    —





    15,636



    Adjusted operating income (loss)



    10,102





    (849)





    (7,619)





    (5,217)





    (23,433)





    (27,016)



     

    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended December 31, 2022



    Operating income (loss)



    (3,898)





    (98,444)





    (12,442)





    (19,543)





    (20,319)





    (154,646)



    Adjustments:





































    Restructuring costs



    —





    —





    —





    212





    —





    212



    Intangible asset impairments



    —





    88,243





    —





    —





    —





    88,243



    Adjusted operating income (loss)



    (3,898)





    (10,201)





    (12,442)





    (19,331)





    (20,319)





    (66,191)



     

    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Year ended December 31, 2023



    Operating income (loss)



    24,630





    4,919





    (112,445)





    11,746





    (91,668)





    (162,818)



    Adjustments:





































    Restructuring costs



    —





    —





    14,446





    —





    5,127





    19,573



    Intangible asset impairments



    —





    —





    29,934





    —





    —





    29,934



    Impairments triggered by restructuring



    —





    —





    15,636





    —





    —





    15,636



    Adjusted operating income (loss)



    24,630





    4,919





    (52,429)





    11,746





    (86,541)





    (97,675)



     

    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Year ended December 31, 2022



    Operating income (loss)



    20,619





    (180,956)





    (29,372)





    (91,275)





    (66,790)





    (347,774)



    Adjustments:





































    Restructuring costs (recovery)



    —





    —





    —





    (670)





    —





    (670)



    Intangible asset impairments



    —





    172,609





    1,850





    —





    —





    174,459



    Adjusted operating income (loss)



    20,619





    (8,347)





    (27,522)





    (91,945)





    (66,790)





    (173,985)



     

    FREE CASH FLOW 

    Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance. Free cash flow provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).



    Three months ended

    December 31



    Year ended

    December 31



    ($000s)

    2023



    2022



    2023



    2022



    Change in cash and cash equivalents



    (6,942)





    (11,841)





    (84,545)





    (278,665)



    Adjustments

























    Repurchase of common shares



    —





    7,241





    1,536





    13,390



    Changes to debt instruments



    —





    —





    —





    10,000



    Changes to long-term investments



    8,325





    17,693





    25,821





    194,735



    Acquisitions, net of cash acquired



    —





    (2,509)





    (3,695)





    28,640



    Free cash flow



    1,383





    10,584





    (60,883)





    (31,900)



     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sndl-reports-full-year-and-fourth-quarter-2023-financial-and-operational-results-302095542.html

    SOURCE SNDL Inc.

    Get the next $SNDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    9/3/2025$5.00Buy
    Alliance Global Partners
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $SNDL
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    2/19/26 4:40:03 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    1/7/26 4:32:18 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    12/15/25 4:36:51 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Provide Update Regarding Arrangement

    EDMONTON, Alberta and TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") announce that they have entered into an amended and restated arrangement agreement (the "A&R Arrangement Agreement") dated December 15, 2025. The A&R Arrangement Agreement amends and restates the arrangement agreement dated April 9, 2025 between 1CM and SNDL (the "Original Arrangement Agreement"), pursuant to which SNDL agreed to, among other things, acquire 32 cannabis retail stores operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the "Transaction") for a purchase price of $32.2 m

    12/15/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Financials

    Live finance-specific insights

    View All

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Third Quarter 2025 Financial and Operational Results

    EDMONTON, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, November 4, 2025. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue: In the third quarter of 2025, net revenue totaled $24

    11/4/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2024 Annual General Meeting Results

    CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

    7/30/24 5:45:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care